Literature DB >> 18782595

Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol.

Paulette R Dillard1, Ming-Fong Lin, Shafiq A Khan.   

Abstract

The proliferation and differentiation of normal prostate epithelial cells depends upon the action of androgens produced by the testis. Prostate cancers retain the ability to respond to androgens in the initial stages of cancer development, but progressively become independent of exogenous androgens in advanced stages of the disease while maintaining the expression of functional androgen receptor (AR). In the present study, we have determined the potential of prostate cancer cells to synthesize androgens from cholesterol which may be involved in intracrine regulation of AR in advanced stages of the disease. Established androgen-independent prostate cancer cell lines, PC3 and DU145 cells, expressed mRNA and proteins for scavenger receptor type B1 (SRB1), steroidogenic acute regulatory (StAR) protein, cytochrome P450 cholesterol side chain cleavage (P450scc), 3beta-hydroxysteroid dehydrogenase (3beta-HSD) and other enzymes involved in androgen biosynthesis. Expression of all these proteins and enzymes was significantly higher in the androgen-independent derivative of LNCaP prostate cancer cells (C81) than in the androgen-dependent cell line (C33). In serum-free cultures, the androgen-independent C81 cells secreted approximately 5-fold higher testosterone than C33 cells as determined in the conditioned media by immunoassays. These cells could also directly convert radioactive cholesterol into testosterone which was identified by thin layer chromatography. These results for the first time show that prostate cancer cells in advanced stages of the disease could synthesize androgens from cholesterol and hence are not dependent upon testicular and/or adrenal androgens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18782595      PMCID: PMC2802176          DOI: 10.1016/j.mce.2008.08.013

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  29 in total

1.  Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.

Authors:  Jeff Holzbeierlein; Priti Lal; Eva LaTulippe; Alex Smith; Jaya Satagopan; Liying Zhang; Charles Ryan; Steve Smith; Howard Scher; Peter Scardino; Victor Reuter; William L Gerald
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

Review 2.  StAR protein and the regulation of steroid hormone biosynthesis.

Authors:  D M Stocco
Journal:  Annu Rev Physiol       Date:  2001       Impact factor: 19.318

Review 3.  The development of androgen-independent prostate cancer.

Authors:  B J Feldman; D Feldman
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

4.  Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry.

Authors:  M El-Alfy; V Luu-The; X F Huang; L Berger; F Labrie; G Pelletier
Journal:  Endocrinology       Date:  1999-03       Impact factor: 4.736

5.  Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

Authors:  Samuel R Denmeade; Lori J Sokoll; Susan Dalrymple; D Marc Rosen; Alyssa M Gady; Debra Bruzek; Rebecca M Ricklis; John T Isaacs
Journal:  Prostate       Date:  2003-03-01       Impact factor: 4.104

6.  Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.

Authors:  Takahito Hara; Kazuyo Nakamura; Hideo Araki; Masami Kusaka; Masuo Yamaoka
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

7.  The androgen axis in recurrent prostate cancer.

Authors:  James L Mohler; Christopher W Gregory; O Harris Ford; Desok Kim; Catharina M Weaver; Peter Petrusz; Elizabeth M Wilson; Frank S French
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

8.  Local aromatase expression in human prostate is altered in malignancy.

Authors:  Stuart J Ellem; Jacqueline F Schmitt; John S Pedersen; Mark Frydenberg; Gail P Risbridger
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

9.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

Review 10.  Molecular biology of the androgen receptor.

Authors:  Edward P Gelmann
Journal:  J Clin Oncol       Date:  2002-07-01       Impact factor: 44.544

View more
  93 in total

1.  Egg, red meat, and poultry intake and risk of lethal prostate cancer in the prostate-specific antigen-era: incidence and survival.

Authors:  Erin L Richman; Stacey A Kenfield; Meir J Stampfer; Edward L Giovannucci; June M Chan
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-19

Review 2.  Therapeutic options for advanced prostate cancer: 2011 update.

Authors:  Aurelius Omlin; Johann S de Bono
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

Review 3.  Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials.

Authors:  Dharam Kaushik; Vishal Vashistha; Sudhir Isharwal; Soud A Sediqe; Ming-Fong Lin
Journal:  Ther Adv Urol       Date:  2015-12

4.  Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.

Authors:  Luciano De Petrocellis; Alessia Ligresti; Aniello Schiano Moriello; Mariagrazia Iappelli; Roberta Verde; Colin G Stott; Luigia Cristino; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 5.  Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives.

Authors:  Nagalakshmi Nadiminty; Allen C Gao
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

6.  Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.

Authors:  Paula Vainio; Santosh Gupta; Kirsi Ketola; Tuomas Mirtti; John-Patrick Mpindi; Pekka Kohonen; Vidal Fey; Merja Perälä; Frank Smit; Gerald Verhaegh; Jack Schalken; Kalle A Alanen; Olli Kallioniemi; Kristiina Iljin
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 7.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

Authors:  William P Harris; Elahe A Mostaghel; Peter S Nelson; Bruce Montgomery
Journal:  Nat Clin Pract Urol       Date:  2009-02

8.  Castration Determines the Efficacy of ETAR Blockade in a Mouse Model of Prostate Cancer Bone Metastasis.

Authors:  Henry H Moon; Katrina L Clines; Mark A Cooks; Charlotte A Cialek; Marian A Esvelt; Gregory A Clines
Journal:  Endocrinology       Date:  2019-08-01       Impact factor: 4.736

9.  Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer.

Authors:  Dannah R Miller; Cherng-Chyi Tzeng; Trey Farmer; Evan T Keller; Steve Caplan; Yu-Shuin Chen; Yeh-Long Chen; Ming-Fong Lin
Journal:  Cancer Lett       Date:  2018-08-03       Impact factor: 8.679

10.  Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.

Authors:  Mengqian Chen; Michael A Feuerstein; Elina Levina; Prateek S Baghel; Richard D Carkner; Matthew J Tanner; Michael Shtutman; Francis Vacherot; Stéphane Terry; Alexandre de la Taille; Ralph Buttyan
Journal:  Mol Cancer       Date:  2010-04-26       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.